The nasal spray is based on Marinomed’s anti-viral respiratory technology platform, mavirex. Respiratory viruses are responsible for the common cold (the most common infectious disease in humans), and Boehringer Ingelheim plans to market the anti-viral nasal spray under the well-known cough and cold brand Mucosolvan®.

‘mavirex’ is Marinomed’s proprietary anti-viral respiratory technology platform to develop therapies that target more than 200 different respiratory virus strains, and Marinomed is investigating the technology for use in a range of other products.

Dr Andreas Grassauer, CEO and co-founder of Marinomed, commented: ‘We are very excited to have signed this deal with Boehringer Ingelheim. Our anti-viral respiratory technology platform has already been validated in clinical trials with adults and children, demonstrating efficacy as an antiviral treatment in treating the cause of the common cold.’

David Wright, Boehringer Ingelheim’s Corporate Senior Vice President, Consumer Healthcare, added: ‘This licensing agreement is an excellent strategic fit with our ongoing development of new and innovative products designed to afford consumers a range of over-the-counter medicines to treat the common cold and related diseases, as well as their associated symptoms.’

Marinomed will receive an upfront payment in the million EUR range from Boehringer Ingelheim, in addition to payments on the achievement of certain market entry milestones and royalties. Further financial details were not disclosed.